Press ReleasesPureForm Global Secures European Food Safety Authority Novel Food...

PureForm Global Secures European Food Safety Authority Novel Food Validation


PureForm Global Inc, through its UK subsidiary PureForm International Ltd, has become the only UK CBD manufacturer to receive validation from the European Commission and the European Food Safety Authority for its Novel Food application.

As European authorities continue to introduce regulations to the CBD market place, PureForm CBD® is the first and only UK CBD manufacturing company producing CBD for sale as a raw ingredient to receive a Validated Novel Food Application from the European Food Safety Authority (EFSA). 

This means that PureForm is in pole position to be amongst the first CBD companies in the world to be granted the much sought after Novel Food License in the EU.

The purpose of the Novel Food application is to ensure safety by way of clinical studies and compliance within the CBD industry so consumers can have access to safe CBD and purchase products with confidence. 

Prior to Novel Foods Regulation, the CBD market had been a relatively poorly regulated sector. The validation of the PureForm CBD® dossier in the EU upholds its position as a leader in the market and goes beyond the industry standard.

Commenting on the validation of their dossier, COO of PureForm Global, Steve Miller said, “At a time when regulators are making it increasingly difficult for companies to import CBD into Europe, we are glad that our production facility in England will be able to supply both the UK and Europe with the highest quality CBD.  The validation from the EFSA is a great boost for our clients and ourselves.”

PureForm CBD® is synthetically produced which means it exceeds the increasingly rigorous standards being required by the Home Office.  

As explained by David McCormick, Head of European Operations, “Saying you have 0% THC (tetrahydrocannabinol) means nothing if you have only tested to parts per thousand. 

We test to parts per million, meaning that even if the Home Office changes to a level of 0.001% THC, our product still meets this standard. This is an exciting first step. But during the second half of the year, we are looking forward to expanding our European offering to include both CBG and CBC, with five additional cannabinoids coming on stream in 2022. We intend to submit Novel Food applications for all of these in due course.

Latest news

Tilray’s Medical Cannabis Product Now Available And Reimbursed Under Ireland’s Medical Cannabis Access Program

PRESS RELEASE TILRAY Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis company inspiring and...

Grow Group, Kanabo, MGC Pharma & Celadon Pharma All Report Growing Revenues, But Continue To Post Losses

AMID the economic chaos that dominated the headlines over the past week, nearly half-a-dozen UK-based or UK-listed cannabis companies...

MGC Pharma Announces Appointment Of UK Advisor And New COO/Deputy CEO

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development...

Sanity Group’s Record Funding Round Led By BAT Could Bring More Big-Tobacco Capital To Cannabis, But Concerns Remain Over Conflicts Of Interest

LAST week Berlin-based cannabis operator Sanity Group closed Europe’s largest ever cannabis investment round worth €37.6m, bringing its total...

European Cannabis Stocks Review: £22m Wiped From LSE-Listed Cannabis Stocks Amid Market Chaos

FOLLOWING a few weeks of relative positivity for many of the stocks listed on the London Stock Exchange (LSE),...

German SPD Representatives Confident A Solution To International Legal Hurdles Will Be Found

EARLIER this month news broke that recent analysis conducted by the Bundestag's scientific service suggested the creation of a...

Must read

You might also likeRELATED
Recommended to you